Related Experiment Video
Updated: Jul 9, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Binding of proteases to fibrillar amyloid-beta protein and its inhibition by Congo red
Harish Chander1, Abha Chauhan, Ved Chauhan
1NYS Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314, USA.
Abstract:
Fibrillar amyloid-beta protein (fAbeta) is the principal component of amyloid plaques in the brains of patients with Alzheimer's disease (AD). We have recently reported that activity of trypsin is inhibited by fAbeta and that trypsin can bind to fAbeta. Neprilysin and insulysin are important proteases for the clearance of soluble Abeta. Here, we report that fAbeta also binds to neprilysin and insulysin, which results in the inhibition of their proteolytic activities. These findings suggest that clearance of soluble Abeta may be defective in AD because of binding of proteases to amyloid plaques, leading to inactivation of proteases that are required for catabolism of Abeta. The identification of compounds that can inhibit binding of proteases to fAbeta may, therefore, be of significance for therapeutic intervention in AD. Congo red and Thioflavin T are widely used for histopathological examination of amyloid plaques because of their strong affinity to fibrillar amyloid proteins. We examined the effect of Congo red and Thioflavin T (potent fAbeta-binding compounds) on the binding of different proteases to fAbeta. While Congo red inhibited the binding of trypsin, neprilysin and insulysin to fAbeta, Thioflavin T did not have any effect. The effect of Congo red was concentration-dependent and the inhibitory effect was in the order of trypsin > insulysin > neprilysin. When the effect of prebound-Congo red to fAbeta was examined, trypsin was unable to bind to this complex suggesting that Congo red may have better affinity than trypsin for binding to fAbeta. Based on these results, we propose that the inhibition of binding of proteases to amyloid plaques may help in reducing the deposition of Abeta in AD.
Insights
Fibrillar amyloid-beta protein (fAbeta) in Alzheimer's disease (AD) inactivates proteases. Congo red prevents protease binding to fAbeta, potentially improving Abeta clearance and reducing plaque deposition in AD.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Fibrillar amyloid-beta protein (fAbeta) forms amyloid plaques in Alzheimer's disease (AD) brains.
- Proteases like trypsin, neprilysin, and insulysin are crucial for clearing soluble Abeta.
- fAbeta binding to these proteases inhibits their activity, potentially impairing Abeta clearance in AD.
Purpose of the Study:
- To investigate the interaction between fAbeta and proteases (trypsin, neprilysin, insulysin).
- To evaluate the effect of Congo red and Thioflavin T on protease binding to fAbeta.
- To explore therapeutic strategies for AD by inhibiting protease-fAbeta interactions.
Main Methods:
- Studied the binding of trypsin, neprilysin, and insulysin to fAbeta.
- Assessed the inhibitory effects of Congo red and Thioflavin T on these interactions.
- Examined the concentration-dependent effects and binding affinity of Congo red.
Main Results:
- fAbeta binds to neprilysin and insulysin, inhibiting their proteolytic activities.
- Congo red, but not Thioflavin T, inhibited the binding of trypsin, neprilysin, and insulysin to fAbeta.
- Congo red's inhibitory effect was concentration-dependent and showed higher affinity than trypsin for fAbeta.
Conclusions:
- Binding of proteases to amyloid plaques may contribute to defective Abeta clearance in AD.
- Congo red inhibits protease binding to fAbeta, suggesting a potential therapeutic approach.
- Inhibiting protease-fAbeta interactions could reduce Abeta deposition and be significant for AD treatment.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

